La Jolla Pharmaceutical Informe acción DB:LJPP Capitalización de mercado
€155.9m
Finanzas de la empresa + 1 Analista
La Jolla Pharmaceutical Company
Informe acción DB:LJPP
Capitalización de mercado: €155.9m
This company listing is no longer active This company may still be operating, however this listing is no longer active. Find out why through their latest events.
See Latest Events Resumen de acción LJPP La Jolla Pharmaceutical Company engages in the development and commercialization of therapies that improve outcomes in patients suffering from life-threatening diseases.
Recompensas Análisis de riesgos Ver todos los controles de riesgos Competidores de La Jolla Pharmaceutical Company Historial de precios y rendimiento
Resumen de todos los máximos históricos, cambios y caídas de precios de La Jolla Pharmaceutical Precios históricos de las acciones Precio actual de la acción US$6.07 Máximo en las últimas 52 semanas US$6.11 Mínimo de 52 semanas US$2.94 Beta 2.41 1Cambio en 1 mes 1.40% Variación en 3 meses 73.44% Cambio de 1 año 93.75% 3Variación en 3 años -33.65% Variación en 5 años -75.48% Variación desde la OPV -99.99%
Noticias y actualizaciones recientes
La Jolla Pharmaceutical Company(NasdaqCM:LJPC) dropped from NASDAQ Composite Index Aug 24 Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of La Jolla Pharmaceutical Company (NasdaqCM:LJPC).
Second quarter 2022 earnings released: EPS: US$0.097 (vs US$0.14 in 2Q 2021) Aug 16
Investor sentiment improved over the past week Jul 13
Innoviva, Inc. (NasdaqGS:INVA) entered into a definitive merger agreement to acquire La Jolla Pharmaceutical Company (NasdaqCM:LJPC) for approximately $150 million. Jul 12
First quarter 2022 earnings released: EPS: US$0 (vs US$0.53 in 1Q 2021) May 17 Ver más actualizaciones
La Jolla Pharmaceutical Company(NasdaqCM:LJPC) dropped from NASDAQ Composite Index Aug 24 Innoviva, Inc. (NasdaqGS:INVA) completed the acquisition of La Jolla Pharmaceutical Company (NasdaqCM:LJPC).
Second quarter 2022 earnings released: EPS: US$0.097 (vs US$0.14 in 2Q 2021) Aug 16
Investor sentiment improved over the past week Jul 13
Innoviva, Inc. (NasdaqGS:INVA) entered into a definitive merger agreement to acquire La Jolla Pharmaceutical Company (NasdaqCM:LJPC) for approximately $150 million. Jul 12
First quarter 2022 earnings released: EPS: US$0 (vs US$0.53 in 1Q 2021) May 17
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Mar 10
Investor sentiment improved over the past week Dec 11
Independent Director recently bought €82k worth of stock Dec 08
Investor sentiment improved over the past week Nov 23
Third quarter 2021 earnings released: US$0.082 loss per share (vs US$0.43 loss in 3Q 2020) Nov 06
Investor sentiment improved over the past week Nov 05
Investor sentiment improved over the past week Aug 28
Second quarter 2021 earnings released: EPS US$0.14 (vs US$0.57 loss in 2Q 2020) Aug 09 La Jolla Pharmaceutical Company(NasdaqCM:LJPC) dropped from Russell 2000 Growth Index
Independent Director recently bought €57k worth of stock May 27
First quarter 2021 earnings released: EPS US$0.53 (vs US$0.32 loss in 1Q 2020) May 08
Full year 2020 earnings released: US$1.44 loss per share (vs US$4.30 loss in FY 2019) Mar 09
Revenue beats expectations Mar 09
New 90-day high: €6.10 Feb 05
La Jolla Pharmaceutical Company Announces Exclusive Licensing Agreement with Paion Ag for Giapreza (Angiotensin Ii) and Xerava (Eravacycline) in Europe Jan 13
New 90-day high: €4.36 Jan 13
Revenue beats expectations Nov 11
Third quarter 2020 earnings released: US$0.43 loss per share Nov 11
New 90-day low: €2.86 Nov 03
La Jolla Pharmaceutical Company Appoints Larry Edwards to Serve as a Member of the Board Oct 31
La Jolla Pharmaceutical Company Announces Management Changes Oct 03
La Jolla Pharmaceutical Company(NasdaqCM:LJPC) dropped from S&P Global BMI Index Sep 21
La Jolla Pharmaceutical Company Announces Resignation of Lakhmir Chawla as Chief Medical Officer Sep 18
Independent Director recently bought €159k worth of stock Aug 25
First half earnings released Aug 07
New 90-day low - €3.18 Aug 07
La Jolla Pharmaceutical Company Appoints Larry Edwards as Chief Executive Officer Jul 31 Rentabilidad de los accionistas LJPP DE Biotechs Mercado DE 7D 1.6% -0.009% -1.2% 1Y 93.7% -17.6% 9.0%
Ver rendimientos de los accionistas
Rentabilidad vs. Industria: LJPP superó a la industria German Biotechs, que obtuvo un rendimiento del -17.6% el año pasado.
Rentabilidad vs. Mercado: LJPP superó al mercado German, que obtuvo un rendimiento del 9% el año pasado.
Volatilidad de los precios Is LJPP's price volatile compared to industry and market? LJPP volatility LJPP Average Weekly Movement 24.2% Biotechs Industry Average Movement 6.2% Market Average Movement 4.8% 10% most volatile stocks in DE Market 10.8% 10% least volatile stocks in DE Market 2.4%
Precio estable de las acciones: El precio de las acciones de LJPP ha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de LJPP ha aumentado de 14% a 24% en el último año.
Acerca de la empresa Mostrar más Resumen de fundamentos de La Jolla Pharmaceutical Company ¿Cómo se comparan los beneficios e ingresos de La Jolla Pharmaceutical con su capitalización de mercado? Estadísticas fundamentales de LJPP Capitalización bursátil €155.85m Beneficios(TTM ) €3.99m Ingresos (TTM ) €46.72m
39.1x Ratio precio-beneficio (PE)
3.3x Ratio precio-ventas (PS) Beneficios e Ingresos Estadísticas clave de rentabilidad del último informe de resultados (TTM) Cuenta de resultados (TTM ) de LJPP Ingresos US$46.49m Coste de los ingresos US$8.87m Beneficio bruto US$37.62m Otros gastos US$33.65m Beneficios US$3.97m
Últimos beneficios comunicados
Jun 30, 2022
Próxima fecha de beneficios
n/a
Beneficios por acción (BPA) 0.16 Margen bruto 80.92% Margen de beneficio neto 8.54% Ratio deuda/patrimonio -179.3%
¿Cómo se ha desempeñado LJPP a largo plazo?
Ver rendimiento histórico y comparativa
Simply Wall St™ Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
{"enabled":false,"variant":{"name":"disabled","enabled":false},"flagsReady":false,"flagsError":null}
